Cargando…

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

BACKGROUND: The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xuan, Tu, Sanfang, Wang, Chunsheng, Huang, Rui, Deng, Lan, Song, Chaoyang, Yue, Chunyan, He, Yanjie, Yang, Jilong, Liang, Zhao, Wu, Anqin, Li, Meifang, Zhou, Weijun, Du, Jingwen, Guo, Zhenling, Li, Yongqian, Jiao, Cheng, Liu, Yuchen, Chang, Lung-Ji, Li, Yuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731732/ https://www.ncbi.nlm.nih.gov/pubmed/33329526 http://dx.doi.org/10.3389/fimmu.2020.564099

Ejemplares similares

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation
por: Li, Meifang, et al.
Publicado: (2019)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway
por: Huang, Rui, et al.
Publicado: (2018)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8
por: TANG, BAISHAN, et al.
Publicado: (2015)

Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
por: Chen, Yiran, et al.
Publicado: (2020)

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
por: Kanwal, Bushra
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
por: Wang, LI, et al.
Publicado: (2023)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
por: Yegya-Raman, Nikhil, et al.
Publicado: (2023)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
por: Niu, Zhi-Yun, et al.
Publicado: (2021)

Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
por: Chen, Jianyu, et al.
Publicado: (2021)

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
por: Li, Ping, et al.
Publicado: (2023)

Changing patterns of relapse in Hodgkin's disease.
por: Duchesne, G., et al.
Publicado: (1989)

Identification of HLA-A*1101-restricted cytotoxic T lymphocyte epitopes derived from epidermal growth factor pathway substrate number 8
por: Lu, Huifang, et al.
Publicado: (2016)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Outcome of children with resistant and relapsed Hodgkin's disease.
por: James, N. D., et al.
Publicado: (1992)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Non-Hodgkin lymphoma with relapses in the lacrimal glands
por: Couceiro, Rita, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Relapse of Hodgkin's disease revealed by skin involvement
por: Abakarim, Ouadii, et al.
Publicado: (2022)

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
por: Zhang, Wen-ying, et al.
Publicado: (2016)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
por: Gaudio, Francesco, et al.
Publicado: (2011)

Paraspinal mass as a presentation in relapsed Hodgkin lymphoma
por: Dua, Vikas, et al.
Publicado: (2013)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
por: Beard, S M, et al.
Publicado: (2000)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2020)

Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases
por: Tu, Sanfang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_seu37i08oa9hf04opcqcorgmba